Publication Date:
2015-04-04
Description:
Immune checkpoint therapy, which targets regulatory pathways in T cells to enhance antitumor immune responses, has led to important clinical advances and provided a new weapon against cancer. This therapy has elicited durable clinical responses and, in a fraction of patients, long-term remissions where patients exhibit no clinical signs of cancer for many years. The way forward for this class of novel agents lies in our ability to understand human immune responses in the tumor microenvironment. This will provide valuable information regarding the dynamic nature of the immune response and regulation of additional pathways that will need to be targeted through combination therapies to provide survival benefit for greater numbers of patients.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Sharma, Padmanee -- Allison, James P -- 1-R01 CA1633793-01/CA/NCI NIH HHS/ -- P30 CA016672/CA/NCI NIH HHS/ -- New York, N.Y. -- Science. 2015 Apr 3;348(6230):56-61. doi: 10.1126/science.aaa8172.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Department of Immunology, M.D. Anderson Cancer Center, Houston, TX, USA. Genitourinary Medical Oncology, M.D. Anderson Cancer Center, Houston, TX, USA. padsharma@mdanderson.org jallison@mdanderson.org. ; Department of Immunology, M.D. Anderson Cancer Center, Houston, TX, USA. padsharma@mdanderson.org jallison@mdanderson.org.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/25838373" target="_blank"〉PubMed〈/a〉
Keywords:
Antibodies, Monoclonal/therapeutic use
;
Antibodies, Monoclonal, Humanized/therapeutic use
;
Antineoplastic Agents/pharmacokinetics/*therapeutic use
;
Biomarkers, Pharmacological
;
CTLA-4 Antigen/antagonists & inhibitors/immunology
;
Combined Modality Therapy
;
Humans
;
Immunotherapy/*methods/*trends
;
Inducible T-Cell Co-Stimulator Protein/immunology
;
Lymphocyte Activation
;
Neoplasms/*drug therapy/pathology
;
Signal Transduction/*drug effects/immunology
;
T-Lymphocytes/*drug effects/immunology
;
Tumor Microenvironment/drug effects/immunology
Print ISSN:
0036-8075
Electronic ISSN:
1095-9203
Topics:
Biology
,
Chemistry and Pharmacology
,
Computer Science
,
Medicine
,
Natural Sciences in General
,
Physics
